<DOC>
	<DOCNO>NCT01595633</DOCNO>
	<brief_summary>In Korea , number suboptimal responder rescue combination therapy also increase . As matter fact , accord investigation Korea , HBV DNA undetectability 48 week adefovir lamivudine combination rescue therapy patient lamivudine resistance report 32.4 % , suggest appropriate another rescue therapy might urgently require . However , promise oral antiviral agent control patient Asia-Pacific region , tenofovir widely available . Tenofovir high potent antiviral efficacy negligible drug resistance rate . The switch adefovir tenofovir patient insufficient hepatitis B virus ( HBV ) suppression ( HBV DNA ≥ 60 IU/mL PCR ) may lead increased viral suppression HBeAg loss/seroconversion . Here , investigator aim conduct randomize study evaluate antiviral efficacy , safety , tolerability switch adefovir tenofovir chronic hepatitis B patient suboptimal response adefovir-based combination rescue therapy due nucleoside analogues Resistance ( SATIS study ) .</brief_summary>
	<brief_title>Switch From Adefovir Tenofovir Chronic Hepatitis B Suboptimal Response Adefovir-based Combination Therapy</brief_title>
	<detailed_description>The major goal antiviral therapy chronic hepatitis B suppress viral replication successfully , ultimately prevent chronic liver damage , development liver cirrhosis hepatocellular carcinoma . In Korea , number multi-drug resistant CHB rapidly increase last year . It national health insurance coverage limit patient experienced primary treatment failure . The switch adefovir allow lamivudine resistant patient thus sequential rescue therapy generate multi-drug resistance adefovir another drug . Thus , nowadays , add-on therapy rather switch therapy might prefer major guideline point . However , number suboptimal responder rescue combination therapy also increase . As matter fact , accord investigation Korea , HBV DNA undetectability 48 week adefovir lamivudine combination rescue therapy patient lamivudine resistance report 32.4 % , suggest appropriate another rescue therapy might urgently require . However , promise oral antiviral agent control patient Asia-Pacific region , tenofovir widely available . Tenofovir high potent antiviral efficacy negligible drug resistance rate . It belong different class compare oral nucleoside analogue ( NAs ) lamivudine , telbivudine , clevudine entecavir . The switch adefovir tenofovir patient insufficient hepatitis B virus ( HBV ) suppression ( HBV DNA ≥ 60 IU/mL PCR ) may lead increased viral suppression HBeAg loss/seroconversion . The result study provide rationale switch adefovir tenofovir combination another drug continue ( lamivudine , telbivudine , clevudine entecavir ) . Here , investigator aim conduct randomize study evaluate antiviral efficacy , safety , tolerability switch adefovir tenofovir chronic hepatitis B patient suboptimal response adefovir-based combination rescue therapy due nucleoside analogues Resistance ( SATIS study ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>subject age &gt; = 20 year subject chronic hepatitis B subject treat nucleoside analogues plus adefovir least 6 month due resistance nucleoside analogue ( Lamivudine , Telbivudine , Entecavir , Clevudine ) subject partial virologic response nucleoside analogues plus adefovir HBV DNA ≥ 60 IU/mL ) subject ALT le 5 time upper limit normal subject agree participate clinical trial sign informed consent subject decompensate liver cirrhosis ChildPugh B , C ) subject Adefovir mutation subject HCV , HDV , HIV infection pregnant lactate woman woman childbearing age use appropriate contraception method subject abnormal lesion suspect hepatocellular carcinoma image modality subject liver disease hemochromatosis , Wilson 's disease , alcoholic liver disease , nonalcoholic liver disease , alpha1 antitrypsin deficiency subject hypersensitivity study drug subject participate clinical trial 60 day current recruitment subject judge inappropriate investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>nucleoside analogue</keyword>
	<keyword>adefovir</keyword>
	<keyword>tenofovir</keyword>
	<keyword>hepatitis B</keyword>
</DOC>